 Mark Gregory
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| fms-Like Tyrosine Kinase 3 | 4 | 2022 | 42 | 1.260 |
Why?
| | Proto-Oncogene Proteins c-myc | 7 | 2012 | 116 | 0.950 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 533 | 0.850 |
Why?
| | Glutamine | 2 | 2019 | 91 | 0.760 |
Why?
| | Benzothiazoles | 2 | 2017 | 31 | 0.710 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 81 | 0.680 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2022 | 636 | 0.650 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 917 | 0.620 |
Why?
| | Benzeneacetamides | 1 | 2017 | 7 | 0.580 |
Why?
| | Glutaminase | 1 | 2017 | 10 | 0.580 |
Why?
| | Thiadiazoles | 1 | 2017 | 21 | 0.570 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 94 | 0.550 |
Why?
| | Leukemia | 1 | 2019 | 208 | 0.550 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.540 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 36 | 0.530 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 48 | 0.530 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2014 | 60 | 0.490 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1875 | 0.480 |
Why?
| | Energy Metabolism | 1 | 2019 | 727 | 0.450 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 695 | 0.390 |
Why?
| | Cell Line, Tumor | 9 | 2022 | 2700 | 0.390 |
Why?
| | Protein Kinase Inhibitors | 6 | 2022 | 784 | 0.360 |
Why?
| | Philadelphia Chromosome | 1 | 2010 | 15 | 0.350 |
Why?
| | NFATC Transcription Factors | 1 | 2010 | 78 | 0.340 |
Why?
| | Wnt Proteins | 1 | 2010 | 134 | 0.320 |
Why?
| | Cell Proliferation | 4 | 2019 | 2173 | 0.310 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2012 | 77 | 0.310 |
Why?
| | Apoptosis | 10 | 2022 | 2349 | 0.310 |
Why?
| | Tumor Suppressor Protein p14ARF | 2 | 2005 | 6 | 0.300 |
Why?
| | Mice, Inbred NOD | 3 | 2017 | 552 | 0.270 |
Why?
| | Calcium | 2 | 2013 | 1089 | 0.250 |
Why?
| | Cell Survival | 3 | 2019 | 1014 | 0.250 |
Why?
| | RNA, Small Interfering | 4 | 2016 | 534 | 0.240 |
Why?
| | Mice | 12 | 2019 | 14843 | 0.230 |
Why?
| | Ubiquitins | 2 | 2000 | 31 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2003 | 552 | 0.210 |
Why?
| | Cysteine Endopeptidases | 2 | 2000 | 60 | 0.210 |
Why?
| | Multienzyme Complexes | 2 | 2000 | 64 | 0.210 |
Why?
| | Cyclosporine | 3 | 2014 | 161 | 0.210 |
Why?
| | Mice, Transgenic | 2 | 2019 | 1947 | 0.210 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 52 | 0.210 |
Why?
| | Peptide Hydrolases | 1 | 2003 | 103 | 0.210 |
Why?
| | Animals | 15 | 2019 | 31565 | 0.210 |
Why?
| | Genes, myc | 2 | 2012 | 46 | 0.200 |
Why?
| | Epididymis | 1 | 2000 | 9 | 0.180 |
Why?
| | Cell Division | 2 | 2004 | 754 | 0.170 |
Why?
| | Hormones | 1 | 2000 | 132 | 0.170 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 427 | 0.160 |
Why?
| | Phosphorylation | 6 | 2022 | 1558 | 0.150 |
Why?
| | Hydrazines | 1 | 2016 | 27 | 0.140 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 522 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1356 | 0.130 |
Why?
| | Transfection | 4 | 2004 | 863 | 0.130 |
Why?
| | Signal Transduction | 5 | 2016 | 4501 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 347 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2017 | 210 | 0.130 |
Why?
| | Oligomycins | 1 | 2014 | 8 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | RNA Interference | 2 | 2014 | 431 | 0.120 |
Why?
| | Imatinib Mesylate | 2 | 2014 | 63 | 0.120 |
Why?
| | Threonine | 2 | 2012 | 40 | 0.120 |
Why?
| | Dasatinib | 2 | 2014 | 45 | 0.120 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 845 | 0.120 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 58 | 0.110 |
Why?
| | Thiazoles | 2 | 2014 | 110 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 949 | 0.110 |
Why?
| | Flow Cytometry | 3 | 2014 | 1075 | 0.110 |
Why?
| | Survival Analysis | 1 | 2016 | 1206 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 211 | 0.110 |
Why?
| | Humans | 17 | 2023 | 114045 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2322 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 57 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2013 | 137 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3498 | 0.100 |
Why?
| | Cell Line | 4 | 2005 | 2629 | 0.100 |
Why?
| | Pyrimidines | 2 | 2014 | 374 | 0.090 |
Why?
| | Blotting, Western | 2 | 2012 | 1143 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 136 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2005 | 445 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 428 | 0.090 |
Why?
| | Amino Acid Substitution | 3 | 2012 | 261 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2012 | 307 | 0.090 |
Why?
| | COS Cells | 2 | 2000 | 175 | 0.090 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2000 | 133 | 0.080 |
Why?
| | Benzamides | 1 | 2010 | 168 | 0.080 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 385 | 0.080 |
Why?
| | Mitosis | 2 | 2000 | 164 | 0.080 |
Why?
| | Female | 6 | 2017 | 59324 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2014 | 4680 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 924 | 0.070 |
Why?
| | Piperazines | 1 | 2010 | 310 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 592 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 641 | 0.070 |
Why?
| | Binding Sites | 2 | 2004 | 1166 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2023 | 743 | 0.050 |
Why?
| | Ubiquitin | 1 | 2003 | 57 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2550 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2005 | 337 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 269 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 1824 | 0.050 |
Why?
| | Mutation | 3 | 2022 | 3338 | 0.050 |
Why?
| | Everolimus | 1 | 2022 | 61 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2005 | 1145 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 154 | 0.050 |
Why?
| | Protein Binding | 2 | 2004 | 1888 | 0.050 |
Why?
| | Growth Inhibitors | 1 | 2000 | 43 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 66 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2004 | 1981 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 255 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 45 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2000 | 140 | 0.040 |
Why?
| | Organ Specificity | 1 | 2000 | 266 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 359 | 0.040 |
Why?
| | Mammary Glands, Animal | 1 | 2000 | 117 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 147 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2000 | 166 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2783 | 0.040 |
Why?
| | Middle Aged | 2 | 2016 | 26605 | 0.040 |
Why?
| | Prostate | 1 | 2000 | 157 | 0.040 |
Why?
| | Tubulin | 1 | 2000 | 122 | 0.040 |
Why?
| | Uterus | 1 | 2000 | 191 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2012 | 22 | 0.040 |
Why?
| | Ovary | 1 | 2000 | 190 | 0.040 |
Why?
| | CHO Cells | 2 | 2012 | 137 | 0.040 |
Why?
| | Cricetinae | 2 | 2012 | 252 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 399 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 613 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2000 | 527 | 0.030 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 796 | 0.030 |
Why?
| | Rats | 2 | 2004 | 4913 | 0.030 |
Why?
| | Fibroblasts | 1 | 2000 | 834 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2004 | 88 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 190 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 315 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 2012 | 1310 | 0.030 |
Why?
| | Early Growth Response Protein 1 | 1 | 2012 | 24 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2012 | 18 | 0.030 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 68 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 213 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2012 | 192 | 0.030 |
Why?
| | Ubiquitination | 1 | 2012 | 86 | 0.030 |
Why?
| | Vinblastine | 1 | 2012 | 63 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 98 | 0.030 |
Why?
| | Cytarabine | 1 | 2012 | 51 | 0.030 |
Why?
| | Peptide Mapping | 2 | 2004 | 60 | 0.030 |
Why?
| | ras Proteins | 1 | 2013 | 138 | 0.030 |
Why?
| | Etoposide | 1 | 2012 | 149 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 228 | 0.020 |
Why?
| | Protein Stability | 1 | 2012 | 156 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 345 | 0.020 |
Why?
| | Wnt Signaling Pathway | 1 | 2013 | 146 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 393 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 213 | 0.020 |
Why?
| | HeLa Cells | 1 | 2012 | 563 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 262 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 607 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 744 | 0.020 |
Why?
| | Brain | 1 | 2000 | 2355 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2562 | 0.020 |
Why?
| | Genomics | 1 | 2013 | 631 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2012 | 3861 | 0.020 |
Why?
| | Okadaic Acid | 1 | 2004 | 11 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 151 | 0.010 |
Why?
| | Carcinogens | 1 | 2004 | 102 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 331 | 0.010 |
Why?
| | Paclitaxel | 1 | 2004 | 190 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 181 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 356 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2004 | 271 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 271 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 771 | 0.010 |
Why?
| | Male | 2 | 2014 | 55396 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 541 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 9049 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1836 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2000 | 293 | 0.010 |
Why?
| | Microtubules | 1 | 2000 | 237 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6077 | 0.010 |
Why?
| | Adult | 1 | 2014 | 30375 | 0.010 |
Why?
|
|
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|